Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Treating Patients with HCV/HIV Coinfection

Hepatology; 2018 Mar; Sikavi, Chen, et al

Patients with hepatitis C virus and human immunodeficiency virus coinfection (HCV/HIV) can be successfully treated with direct-acting antivirals (DAAs), which have resulted in similarly high rates of sustained virologic response (SVR) for HCV infection in those with and without HIV infection. This according to a recent review of studies for this “special population” of patients between January 2004 and July 2017. Among the findings:

  • SVR rates for those with HCV/HIV coinfection treated with interferon-based therapies were substantially lower than SVR rates of HCV-monoinfected individuals.
  • DAA agents has resulted in similar SVR rates between monoinfected and coinfected individuals, with SVR >93%.
  • Clinicians should be aware of negative predictors of SVR and barriers to treatment that may be more common in coinfected individuals.

Citation:

Sikavi, C, Chen PH, Lee AD, Saab EG, Choi G, Saab S. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population. Hepatology. 2018;67(3):847–857. doi:10.1002/hep.29642.

This Week's Must Reads

HCV Screening Program in a Large Birth Cohort, Open Forum Infect Dis; ePub 2018 Mar 26; Cornett, et al

Do Electronic Reminders Aid in HCV Screening?, J Viral Hepat; ePub 2018 Mar 30; MacLean, et al

HCV Screening Shows Minimal Increase Overall , Cancer Epidemiol Biomarkers Prev; 2018 Apr; Kasting, et al

Improving Access to HCV Medications, J Manag Care Spec Pharm; 2018 Apr; Vu, et al

Previous HBV & Clinical Outcomes in HCV, J Viral Hepat; ePub 2018 Mar 25; Wang, et al

Must Reads in Hepatitis

HCV Screening Program in a Large Birth Cohort, Open Forum Infect Dis; ePub 2018 Mar 26; Cornett, et al

Do Electronic Reminders Aid in HCV Screening?, J Viral Hepat; ePub 2018 Mar 30; MacLean, et al

HCV Screening Shows Minimal Increase Overall , Cancer Epidemiol Biomarkers Prev; 2018 Apr; Kasting, et al

Improving Access to HCV Medications, J Manag Care Spec Pharm; 2018 Apr; Vu, et al

Previous HBV & Clinical Outcomes in HCV, J Viral Hepat; ePub 2018 Mar 25; Wang, et al